Evidence map›Paper›PMID 40730572›Full record

ArticleInternational journal of oral science2025

c-Kit signaling confers damage-resistance to sweet taste cells upon nerve injury.

Su Young Ki, Jea Hwa Jang, Dong-Hoon Kim, Yong Taek Jeong

Abstract read
In one paragraph

Article in International journal of oral science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Su Young Ki *Department of Pharmacology, Korea University College of Medicine, Seoul, Republic of Korea.
Jea Hwa Jang *Department of Pharmacology, Korea University College of Medicine, Seoul, Republic of Korea.
Dong-Hoon KimDepartment of Pharmacology, Korea University College of Medicine, Seoul, Republic of Korea. ldhkim@korea.ac.kr.
Yong Taek JeongDepartment of Pharmacology, Korea University College of Medicine, Seoul, Republic of Korea. jyongtaek@korea.ac.kr.ORCID 0000-0003-0067-6396

Funding

Korea Health Industry Development Institute (KHIDI) RS-2024-00403511National Research Foundation of Korea (NRF) RS-2023-00208193
6 · The paper itself

Abstract

Taste buds relay taste sensory information to the primary taste neurons but depend on those same neurons for essential components to maintain function. While denervation-induced taste bud degeneration and subsequent regeneration were discovered decades ago, the mechanisms underlying these phenomena (e.g., heterogenous cellular responses to nerve injury and the signaling pathways involved) remain poorly understood. Here, using mouse genetics, nerve injury models, pharmacologic manipulation, and taste bud organoid models, we identify a specific subpopulation of taste cells, predominantly c-Kit-expressing sweet cells, that exhibit superior resistance to nerve injury. We found the c-Kit inhibitor imatinib selectively reduced the number of residual c-Kit-expressing sweet cells at post-operation week 2, subsequently attenuating the re-emergence of other type II cells by post-operation week 4. In taste bud organoids, c-Kit-expressing cells were resistant to R-spondin withdrawal but susceptible to imatinib, while other taste cell types showed the opposite behavior. We also observed a distinct population of residual taste cells that acquired stem-like properties, generating clonal descendent cells among suprabasal keratinocytes independent of c-Kit signaling. Together, our findings reveal that c-Kit signaling confers resilience on c-Kit-expressing sweet cells and supports the broader reconstruction of taste buds during the later regenerative stage following nerve injury.

Indexed as

Proto-Oncogene Proteins c-kitSignal TransductionTaste BudsAnimalsImatinib MesylateMiceMice, Inbred C57BLImatinib MesylateProto-Oncogene Proteins c-kit

Identifiers

PMID40730572
PMCPMC12307918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.